Nirogacestat
Gamma Secretase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: nirogacestat hydrobromide, ogsiveo, PF-03084014, PF-03084014-04
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Nirogacestat is an onp drug in the Gamma Secretase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 3A Inhibitors and Gamma Secretase Inhibitors. DrugCentral lists 1 molecular target, including PSEN1. Recorded indications include Progressing desmoid tumors.
- Approval status: onp (first approved 2023 by the FDA).
- Drug class: Gamma Secretase Inhibitor.
- Mechanism of action: Cytochrome P450 2C19 Inducers; Cytochrome P450 3A Inhibitors; Gamma Secretase Inhibitors.
- Molecular targets: PSEN1 (1 listed in DrugCentral).
- Indications: Progressing desmoid tumors.
- ATC code: L01XX81 (Other antineoplastic agents).
- Molecular formula: C27H41F2N5O; molecular weight 489.66 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Progressing desmoid tumors
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 2C19 Inducers; Cytochrome P450 3A Inhibitors; Gamma Secretase Inhibitors |
|---|---|
| Established pharmacologic class | Gamma Secretase Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Presenilin-1 | PSEN1 | inhibitor | IC50 8.21 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-11-27 | FDA | — | SPRINGWORKS | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01XX81 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: APC, CTNNB1
- FDA label: APC, CTNNB1
- HCSC label: APC, CTNNB1
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Diarrhoea | 121.1 |
| Hidradenitis | 92.7 |
| Hypophosphataemia | 55.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Nirogacestat is on its molecule page.
| Molecular formula | C27H41F2N5O |
|---|---|
| Molecular weight | 489.66 g/mol |
| CAS number | 1290543-63-3 |
| InChIKey | VFCRKLWBYMDAED-REWPJTCUSA-N |
| PubChem CID | 46224413 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Nirogacestat used for?
DrugCentral lists the following indications for Nirogacestat: Progressing desmoid tumors.
How does Nirogacestat work?
Nirogacestat is classified as Cytochrome P450 2C19 Inducers, Cytochrome P450 3A Inhibitors and Gamma Secretase Inhibitors; its molecular targets in DrugCentral include PSEN1 (inhibitor).
When was Nirogacestat first approved?
Nirogacestat was first approved by the FDA in 2023.
What drug class does Nirogacestat belong to?
Nirogacestat is in the Gamma Secretase Inhibitor class.
What is the chemical formula of Nirogacestat?
Nirogacestat has the molecular formula C27H41F2N5O and a molecular weight of 489.66 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5753 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1770916 — compound record and bioactivity
- PubChem CID 46224413 — chemical identifiers
- DrugBank DB12005 — drug record
- FDA UNII QZ62892OFJ — substance identity
- DailyMed: FDA labels for Nirogacestat — current prescribing information (label search)
- UniProt P49768 (PSEN1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.